1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 United States HIV Drugs Market - Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 United States HIV Drugs Market Landscape
5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)
6 United States HIV Drugs Market - Breakup by Drug Class
6.1 Nucleoside Reverse Transcriptase Inhibitors
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2019-2024)
6.1.3 Market Forecast (2025-2033)
6.2 Multi-Class Combination Products
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2019-2024)
6.2.3 Market Forecast (2025-2033)
6.3 Protease Inhibitors
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2019-2024)
6.3.3 Market Forecast (2025-2033)
6.4 HIV Integrase Strand Transfer Inhibitors
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2019-2024)
6.4.3 Market Forecast (2025-2033)
6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
6.5.1 Overview
6.5.2 Historical and Current Market Trends (2019-2024)
6.5.3 Market Forecast (2025-2033)
6.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist
6.6.1 Overview
6.6.2 Historical and Current Market Trends (2019-2024)
6.6.3 Market Forecast (2025-2033)
6.7 Fusion Inhibitors
6.7.1 Overview
6.7.2 Historical and Current Market Trends (2019-2024)
6.7.3 Market Forecast (2025-2033)
6.8 Others
6.8.1 Historical and Current Market Trends (2019-2024)
6.8.2 Market Forecast (2025-2033)
7 United States HIV Drugs Market - Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2019-2024)
7.1.3 Market Forecast (2025-2033)
7.2 Retail Pharmacies
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2019-2024)
7.2.3 Market Forecast (2025-2033)
7.3 Online Pharmacies
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2019-2024)
7.3.3 Market Forecast (2025-2033)
7.4 Others
7.4.1 Historical and Current Market Trends (2019-2024)
7.4.2 Market Forecast (2025-2033)
8 United States HIV Drugs Market – Breakup by Region
8.1 Northeast
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2019-2024)
8.1.3 Market Breakup by Drug Class
8.1.4 Market Breakup by Distribution Channel
8.1.5 Key Players
8.1.6 Market Forecast (2025-2033)
8.2 Midwest
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2019-2024)
8.2.3 Market Breakup by Drug Class
8.2.4 Market Breakup by Distribution Channel
8.2.5 Key Players
8.2.6 Market Forecast (2025-2033)
8.3 South
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2019-2024)
8.3.3 Market Breakup by Drug Class
8.3.4 Market Breakup by Distribution Channel
8.3.5 Key Players
8.3.6 Market Forecast (2025-2033)
8.4 West
8.4.1 Overview
8.4.2 Historical and Current Market Trends (2019-2024)
8.4.3 Market Breakup by Drug Class
8.4.4 Market Breakup by Distribution Channel
8.4.5 Key Players
8.4.6 Market Forecast (2025-2033)
9 United States HIV Drugs Market – Competitive Landscape
9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant
10 Profiles of Key Players
10.1 Company A
10.1.1 Business Overview
10.1.2 Product Portfolio
10.1.3 Business Strategies
10.1.4 SWOT Analysis
10.1.5 Major News and Events
10.2 Company B
10.2.1 Business Overview
10.2.2 Product Portfolio
10.2.3 Business Strategies
10.2.4 SWOT Analysis
10.2.5 Major News and Events
10.3 Company C
10.3.1 Business Overview
10.3.2 Product Portfolio
10.3.3 Business Strategies
10.3.4 SWOT Analysis
10.3.5 Major News and Events
10.4 Company D
10.4.1 Business Overview
10.4.2 Product Portfolio
10.4.3 Business Strategies
10.4.4 SWOT Analysis
10.4.5 Major News and Events
10.5 Company E
10.5.1 Business Overview
10.5.2 Product Portfolio
10.5.3 Business Strategies
10.5.4 SWOT Analysis
10.5.5 Major News and Events
Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.
11 United States HIV Drugs Market - Industry Analysis
11.1 Drivers, Restraints, and Opportunities
11.1.1 Overview
11.1.2 Drivers
11.1.3 Restraints
11.1.4 Opportunities
11.2 Porters Five Forces Analysis
11.2.1 Overview
11.2.2 Bargaining Power of Buyers
11.2.3 Bargaining Power of Suppliers
11.2.4 Degree of Competition
11.2.5 Threat of New Entrants
11.2.6 Threat of Substitutes
11.3 Value Chain Analysis
12 Appendix